Strong Buy Rating for Cybin Inc. on Promising Clinical Advances and Strategic Management Positioning
Cybin Is Maintained at Buy by Canaccord Genuity
Cybin Analyst Ratings
Cybin Analyst Ratings
Cybin's Promising Psychedelic Treatments Bolster Buy Rating and $5 Price Target
Cybin Analyst Ratings
Cybin Analyst Ratings
Cybin Analyst Ratings
Cybin's CYB003 Shows Promise in MDD Treatment, Justifying Buy Rating
Buy Rating Affirmed for Cybin on Promising CYB003 Clinical Data and Strategic FDA Designations
Cybin Analyst Ratings
Cybin (CYBN) Gets a Buy From Oppenheimer
Cybin Analyst Ratings
Promising Futures for Cybin's Psychedelic Treatments: A Buy Rating Analysis
Oppenheimer Sticks to Their Buy Rating for Cybin (CYBN)
Buy Rating Affirmed for Cybin Based on Advancements in Psychedelic Treatments and Optimistic Valuation
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cybin (CYBN), Nevro Corp (NVRO) and Biogen (BIIB)
Analysts Conflicted on These Healthcare Names: Protara Therapeutics (TARA), Cybin (CYBN) and Roche Holding AG (OtherRHHVF)
Analysts Offer Insights on Healthcare Companies: Cybin (CYBN), ADMA Biologics (ADMA) and Halozyme (HALO)
Cybin Analyst Ratings